Top-line Growth is Likely to Be Driven by CASI Pharmaceuticals Inc (CASI) Stock
BTIG Research raised the price target for the CASI Pharmaceuticals Inc (NASDAQ:CASI) stock to “a Buy”. The rating was released on May 18, 2021, according to finviz. The research report from Oppenheimer has initiated the stock to Outperform, with a price target set at $5. The stock was initiated by Maxim Group, who disclosed in […]
